Novel blood-based biomarkers for dementia could identify disease at an early preclinical stage, serve as surrogate outcomes for clinical trials of investigational therapies and even identify future potential therapeutic targets.
Read More
Novel blood-based biomarkers for dementia could identify disease at an early preclinical stage, serve as surrogate outcomes for clinical trials of investigational therapies and even identify future potential therapeutic targets.
Read More